Tag Archives: month

U.S. Fund Flows: Equity Funds Get Back In The Game

By Patrick Keon Thomson Reuters Lipper’s fund macro-groups (including both mutual funds and exchange-traded funds [ETFs]) took in over $13.2 billion of net new money during the fund-flows week ended Wednesday, March 9. All four of the fund macro-groups experienced positive net flows for the week; taxable bond funds were at the head of the table with net inflows of $5.8 billion, followed by equity funds (+$4.6 billion), money market funds (+$2.4 billion), and municipal bond funds (+$518 million). The positive flows into equity funds reversed a nine-week trend of investors pulling money out of the group. The equity markets continued their comeback during the week. After losing over 11.4% during the first six weeks of the year the S&P 500 Index recorded its fourth straight week of positive returns. The index gained back over 7.2% during this four-week timeframe, including this past week’s 0.1% appreciation. The market took strength during the week from a rally in oil prices. U.S. crude hit a three-month high ($38.51) during the week and experienced increases in seven of the last eight trading sessions. An increased demand for gas overpowered the record-high crude oil stockpiles to drive the price of oil higher. Another positive for the market was a strong jobs report as nonfarm payrolls grew by 242,000 jobs. The jobs report reinforced the belief that a recession was not in the cards for the near term and also opened the door to the possibility of more interest rate hikes by the Federal Reserve in 2016. The majority of the net inflows for taxable bond funds belonged to mutual funds (+$3.4 billion), while ETFs contributed $2.4 billion to the total. On the mutual fund side the largest net inflows belonged to funds in Lipper’s High Yield Funds classification (+$1.6 billion), while investment-grade debt categories Lipper Core Plus Bond Funds and Lipper Core Bond Funds took in $735 million and $657 million of net new money, respectively. The two largest individual net inflows for ETFs belonged to the iShares Core US Aggregate Bond (NYSEARCA: AGG ) (+$687 million) and the iShares JPMorgan USD Emerging Market Bond (NYSEARCA: EMB ) (+$528 million). ETFs (+$4.2 billion) accounted for the majority of the net inflows for equity funds for the week, while mutual funds pitched in $400 million of net new money. The largest net inflows among individual ETFs belonged to the iShares MSCI Emerging Markets (NYSEARCA: EEM ) (+$853 million) and the iShares Russell 2000 (NYSEARCA: IWM ) (+$535 million), while for mutual funds nondomestic equity funds had positive flows of $416 million and domestic equity funds suffered slight net outflows of $16 million. The week’s net inflows for municipal bond mutual funds (+$450 million) were the twenty-third consecutive weekly gains for the group. Funds in the Intermediate Muni Debt Funds (+$166 million) and General Muni Debt Funds (+$117 million) categories posted the largest net inflows for the week. The net inflows into money market funds (+$2.4 billion) marked the fourth consecutive week in which the group experienced positive flows. The group grew its coffers by over $13.3 billion during this four-week run. The largest contributors to this past week’s gains were Institutional U.S. Money Market Funds (+$7.5 billion) and Institutional U.S. Government Money Market Funds (+$2.8 billion), while Institutional U.S. Treasury Money Market Funds had net outflows of over $4.7 billion.

Don’t Be Fooled By The Short Squeeze

By Alan Gula, CFA On November 18, 2015, KaloBios Pharmaceuticals Inc. ( OTCPK:KBIOQ ) announced that Martin Shkreli and a consortium of investors had acquired more than 50% of its outstanding shares. The stock, which had closed at $2.07 that day, traded above $10 the day after the announcement. The next day, shares rose above $23 and closed at $18.45. The following Monday, the stock miraculously traded for over $45 per share. In just six trading days, the market cap of KaloBios had risen from under $4 million to over $160 million. It was a blatant example of market inefficiency. But what could cause such an irrational spike? The answer is an acute “short squeeze.” A sharp rally in the price of a stock puts pressure on short sellers, who are betting the stock will fall. They may feel the need (or be forced) to close out their short sales by buying the stock. The buying pressure from this short covering causes the stock to move higher, compelling even more traders to cover their shorts. Over the past month, we’ve seen a bevy of short squeezes as the U.S. stock market has bounced along with the price of crude oil. These squeezes haven’t been as spectacular as the above example, but judging by how heavily shorted some of these stocks are, they’ve been very painful for the short sellers, nonetheless. The following table shows a few of the largest squeezes: The short interest ratio (SIR) is the number of shares sold short divided by the average daily trading volume. The average SIR for S&P 500 constituents is 3.3 times. At 9.5 times, the average SIR for these stocks is much higher – and for good reason. The risk of bankruptcy is very high for the companies on this list. Thus, they all have Standard & Poor’s credit ratings of CCC+ or lower. Two of the companies are already in selective default (SD). Others will eventually join them. Many of the stocks on this list will end up worthless. Risks notwithstanding, the short squeezes have been eye watering. Chesapeake Energy Corp. (NYSE: CHK ) shot up 208%. Linn Energy LLC (NASDAQ: LINE ) annihilated the shorts with a 398% maximum gain over the past month. In spite of these equity gains, though, many of these companies won’t have fairy tale endings. For example, the 6% bonds due 11/15/2018 for Peabody Energy Corp. (NYSE: BTU ) have rallied, but they’re still trading around $7 ($100 par). The bond market is saying that there won’t be much recovery for senior unsecured creditors, which means that equity shareholders will be left with approximately zero. The equity shareholders of the companies listed above are deluding themselves if they think the market cap reflects underlying fundamentals. It’s important to recognize that a sharp rally in a stock doesn’t necessarily signal all is well. In most cases, these stocks aren’t rising from the ashes. In fact, many of the companies with the most violent short squeezes will end up filing for bankruptcy, just as KaloBios had to do on December 30, 2015. Safe (and high-yield) investing. Original Post Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Investors Need To Understand The Risks Of Smart Beta

By Rhea Wessel The low-yield environment has many investors seeking new sources of outperformance. One development has been the growth of so-called smart beta investments, a $400 billion ETF market with a strong flow of funds from both institutions and retail investors. But are such funds really “smart” and do they truly have the potential to boost performance? To answer such questions, CFA Institute Magazine turned to Nick Baturin, CFA , formerly head of portfolio analytics at Bloomberg. He also spoke at the CFA Institute Annual Conference in Frankfurt in 2015. In this interview, Baturin discusses the rise of smart beta, its counterpart “dumb alpha,” and the need for investors to educate themselves about risks in this area. CFA Institute: First of all, what is smart beta? Nick Baturin, CFA : Smart beta investments are funds and ETFs that have a non-traditional weighting scheme that goes beyond cap weighting. There are many different types out there – equal-weighted, inversely risk-weighted, optimized to minimize risk, fundamental-weighted, factor tilts, dividend tilts, and dividend-weighted ETFs. There’s a whole taxonomy out there. The latest entrant in this space is a hybrid product which combines several themes into one. An example is the iShares enhanced index funds. These are active funds and they trade based on some of BlackRock’s research into well-known anomalies – the value anomaly, the quality anomaly, the size anomaly – and they optimize risk as well. They act like an active management quant fund but somewhat simplified. BlackRock does not give you all of their proprietary model insights that they use for their other actively managed quant funds. They give you a dumbed-down version of that. However, they’re also charging lower fees than for their actively managed quant funds. Another thing to note about smart beta indices: They have to rebalance a lot more often than passive buy-and-hold index funds, which are cap-weighted and typically rebalance just once or twice a year. You’ve talked about “dumb alpha.” What is that? There’s a lot of marketing hype going on. When I call smart beta “dumb alpha,” that’s a view that’s somewhat non-traditional. Obviously, it wouldn’t sit well with smart beta fund providers. I call it dumb alpha because traditional quantitative investors have known about these style tilts for several decades. They bet on factors such as value and momentum, quality and size. These have been used in quant investment strategies forever. I call them generic alpha factors rather than proprietary alpha factors. The difference between generic and proprietary is that proprietary cannot be easily replicated. You have some secret sauce, perhaps, at your own firm that only you know about, whereas with a value factor or size or momentum, everyone knows about it. You can implement this in a very straightforward manner. In that sense, it’s dumb alpha because you don’t need any complex implementation engine for it. What I’ve seen with smart beta is partially a marketing effort to rebrand these traditional generic alpha factors as smart beta funds. All they do is give you exposure to these traditional, generic quant factors, but in the ETF wrapper, and they charge a higher fee. So, basically, it’s a rebranding effort in my opinion. Is the higher fee justified? Well, the higher fee can be partially justified by the higher trading costs of these funds. And certain factors do have long-term outperformance records over the market portfolio. But you have to be very judicious. With a smart beta fund, the burden of decision as to what to invest in is no longer on the fund manager. It’s now on the investor. Should smart beta strategies be included in participant retirement plans? Fundamentally weighted funds bet on the value factor, but investors can also get value-factor exposure by investing in the Vanguard Value Fund, which is a cap-weighted fund which also gives you value exposure, but a lot cheaper. You have to be judicious. You cannot expect a retail investor to know the difference between smart beta and stupid beta and to evaluate the cost versus benefit tradeoff. If you call all smart beta ETFs “smart,” that becomes a confusing soup to choose from. You have momentum, you have value, you have quality, you have size; you have fundamental-weighted, risk-weighted. It’s a complicated array of products that is exposing retail investors to a lot more choices. This will take them a long time to learn about. I don’t think they are in a position to really drill down in much detail. Would I include smart beta in participant retirement plans? Possibly, but you have to select low-cost versions implementing well-known ideas that have been demonstrated to work over a long time and in different markets, like a value tilt. That’s a pretty solid factor. That’s one of the best ones out there. Is a fundamentally weighted index a good way to capture that? A fundamental index comes with additional attributes (factor exposures other than value) that are offered as a bundled deal. In that sense, a pure value tilt is probably a better exposure vehicle for retirement plans. If you are a retail investor, you are typically not sophisticated, and you respond to marketing and hype. It’s our job as investment managers to be honest with these investors and really explain performance beyond the hype. They have to know the risks and the rewards of investing in these products, and there are risks. The term smart beta is a great marketing slogan, and it has caught on. What are the risks? You may have a period of massive underperformance of a particular strategy. There’s a lot of academic research that says that actively managed funds collectively underperform passive cap-weighted indices in the long run. Vanguard founder John Bogle thinks that everything that’s not an index fund is a fraud. But does it mean that the market is truly efficient and there are no anomalies? No. There are anomalies. And there are risks – mainly, that any strategy will underperform. Let’s say everybody in the world piles into value strategies. Then value will stop working. The market-cap-weighted index is the only index that can theoretically be held by every investor in the market. You will all get the same exposure. But in the real world, there will always be some winners and some losers. After a lot of dollars flow into these smart beta funds, they will eventually stop working. We’ll have cut off the branch we were sitting on. What’s next in the world of smart beta? I’d say hybrid products that erase the boundary between active management and smart beta are where things are headed. Those are truly multi-factor, risk-aware investment strategies. These haven’t caught on just yet. The largest is just over 100 million in assets. That’s not a lot by the standards of the ETF market. But, nevertheless, these hybrid products that combine several anomalies in a risk-controlled way under one vehicle will become popular. It depends on the performance and the marketing. I think the marketing is a huge aspect of it all. We live in a low-yield environment with investors who are desperate to outperform the traditional indices and asset classes, so I think marketing has a huge role to play in whether or not these hybrid products catch on. What should investors watch out for in smart beta? There are definitely things to watch out for. I’d say don’t start out cold. You’ve got to educate yourself. Beware of risks. Beware of costs. Invest in more robust ideas, like value. Momentum isn’t robust. On that basis, my heart lies with lower-cost solutions that offer you a cheap value tilt. These are traditional cap-weighted value funds. They score highly for me because they are cheap and deliver on that factor tilt. There’s going to be periods of underperformance. At least over the very long term, you stand a chance of outperforming traditional cap-weighted indices. Disclaimer: Please note that the content of this site should not be construed as investment advice, nor do the opinions expressed necessarily reflect the views of CFA Institute.